Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy
暂无分享,去创建一个
F. Montorsi | G. Gandaglia | A. Briganti | R. Karnes | S. Shariat | A. Martini | M. Moschini | E. Xylinas | C. Simeone | A. Stabile | M. Álvarez-Maestro | O. de Cobelli | R. Colombo | A. Gallina | A. Mattei | M. Soligo | C. Lonati | G. Simone | E. di Trapani | S. Zamboni | L. Afferi | J. G. Schultz | E. Di Trapani
[1] Kevin Crosby,et al. Copyright 2021 , 2021, 2021 25th International Computer Science and Engineering Conference (ICSEC).
[2] W. Sexton,et al. Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy. , 2020, The Journal of urology.
[3] M. Galsky,et al. What Is the Significance of Variant Histology in Urothelial Carcinoma? , 2020, European urology focus.
[4] S. Daneshmand,et al. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. , 2020, European urology focus.
[5] V. Miller,et al. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. , 2020, European urology.
[6] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[7] M. Babjuk,et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. , 2019, European urology.
[8] J. Witjes,et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Gu , 2019, European urology oncology.
[9] Adam T Froemming,et al. ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer. , 2019, Journal of the American College of Radiology : JACR.
[10] F. Montorsi,et al. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent , 2019, World Journal of Urology.
[11] S. Lipsitz,et al. Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. , 2019, Clinical Genitourinary Cancer.
[12] L. Egevad,et al. The natural history of untreated muscle‐invasive bladder cancer , 2019, BJU international.
[13] M. Mazumdar,et al. Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States , 2018, JNCI cancer spectrum.
[14] Anthony Patterson,et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] T. Garg,et al. Burden of Multiple Chronic Conditions among Patients with Urological Cancer , 2018, The Journal of urology.
[16] M. Menon,et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology , 2017, Cancer.
[17] A. Lafranconi,et al. Intensive follow-up for women with breast cancer: review of clinical, economic and patient’s preference domains through evidence to decision framework , 2017, Health and Quality of Life Outcomes.
[18] J. Cheville,et al. Oncologic surveillance following radical cystectomy: an individualized risk-based approach , 2017, World Journal of Urology.
[19] S. Shariat,et al. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery , 2016, Translational andrology and urology.
[20] A. Martini,et al. Use of sigmoid colon in orthotopic neobladder reconstruction: Long‐term results , 2016, International journal of urology : official journal of the Japanese Urological Association.
[21] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[22] Holger Moch,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.
[23] S. Selph,et al. Treatment of muscle‐invasive bladder cancer: A systematic review , 2016, Cancer.
[24] J. Cheville,et al. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Cheville,et al. Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. , 2015, Urologic oncology.
[26] C. Stief,et al. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. , 2014, European urology.
[27] J. Witjes,et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.
[28] B. Bochner,et al. Pathological response to neoadjuvant chemotherapy for muscle‐invasive micropapillary bladder cancer , 2013, BJU international.
[29] J. Clarke,et al. What is a systematic review? , 2011, Evidence Based Nursing.
[30] K. Carroll,et al. On the use and utility of the Weibull model in the analysis of survival data. , 2003, Controlled clinical trials.
[31] M. Indelli,et al. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. , 1994, JAMA.
[32] Adam T Froemming,et al. Post-Treatment Surveillance of Bladder Cancer , 2019 .